Q-omics provides the consensus-scored CACNA1C-IT2 profile across patient tissues and cancer cell-line models. CACNA1C-IT2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CACNA1C-IT2 is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, CACNA1C-IT2 RNA expression shows 9,303 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, UCEC, and TGCT as cancer lineages where CACNA1C-IT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA1C-IT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA1C-IT2 survival associations across molecular data types. CACNA1C-IT2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA1C-IT2 RNA expression–survival associations across cancer types. High CACNA1C-IT2 expression shows unfavorable associations in BRCA, ACC, READ and SKCM, but favorable associations in CHOL and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CACNA1C-IT2 RNA expression.
This table summarizes CACNA1C-IT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA1C-IT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA1C-IT2 shows lower tumor expression in UCEC, BLCA, READ and PRAD and higher tumor expression in THCA and HNSC. The UCEC box plot shows higher CACNA1C-IT2 RNA expression in normal versus tumor tissue (log2 FC = −0.508, t-test p < 0.001).
This table shows molecular features associated with CACNA1C-IT2 in patient tissues and cancer cell lines. In patient samples, CACNA1C-IT2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
